<DOC>
	<DOCNO>NCT00283504</DOCNO>
	<brief_summary>The researcher propose assess level sputum inflammatory marker ( eosinophil , eosinophil cationic protein ( ECP ) , neutrophils IL-8 ) anti-IgE therapy pediatric population moderate severe asthmatic ongoing persistent asthma symptom despite moderate high dos inhale corticosteroid ( ICS ) . Associations assess type sputum inflammatory marker patient 's atopic status level asthma control indicate follow measure : 1. pulmonary function test ( PFT ) 2. asthma symptom base Asthma Control Test ( ACT )</brief_summary>
	<brief_title>A Description Inflammatory Cell Types In Moderate Severe Pediatric Asthma : Eosinophilic Non Eosinophilic Sputum Markers While Anti-IgE Therapy</brief_title>
	<detailed_description>Objectives : Primary : Describe inflammatory cell type study patient compare change inflammatory cell pattern anti-IgE therapy . Secondary : Describe pattern sputum eosinophilia neutrophilia relation asthma symptom improvement base ACT PFT Hypotheses : Differences inflammatory response addition anti-IgE therapy describe neutrophilic , eosinophilic neutrophilic/eosinophilic asthmatic . Neutrophilic asthmatic patient fail respond place anti-IgE eosinophilic asthmatic respond well . Sputum inflammatory marker sensitive marker inflammation predict response new asthma treatment modality anti-IgE therapy .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Anti-Idiotypic</mesh_term>
	<criteria>Moderate severe allergic asthma , uncontrolled conventional therapy History systemic illness , currently immune modulators like immunotherapy , IVIg Pregnancy IgE level &gt; 1300</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>